A new European Union (EU)-funded project is set to provide accessible and reliable information about cell and gene-based therapies in Scotland. Known as EuroGCT, its project team hosted by the Centre for Regenerative Medicine will coordinate Europe-wide collaboration which also includes MRC Human Genetics Unit, Roslin Institute and Centre for Cardiovascular Science. This €2 million initiative represents an online hub to offer accurate information on the use of cells and genetic materials to treat disease coupled with evidence-based information to counter misinformation surrounding the therapies.
Led by the University of Edinburgh, the European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT) unites 49 partner organizations and institutions across Europe, including the major European advanced therapies learned societies, with the common goal of providing reliable and accessible information related to cell and gene therapy development to European stakeholders. EuroGCT has two major objectives, including 1) provide patients, people affected by conditions, healthcare professionals and citizens with accurate scientific, legal, ethical and societal information and with engagement opportunities, and thus to support better decision making, and 2) as related to cell and gene-based therapies to facilitate better decision-making at key points in development of new therapies and thus enable improved product development, by offering the research community and regulatory and healthcare authorities with a valuable information source.
Five Year Online Effort
The five-year project helps coordinate information from EuroGCT partners to develop a multilingual website that offers patients, healthcare professionals and the public reliable scientific, legal and ethical information related to cell and gene-based therapies.
EuroGCT is funded by the European Union’s Horizon 2020 research and innovation programme.